Adrenergic Uptake Inhibitors
Research News and Information

Monday, November 23, 2009

Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands.

21 Oct 2009 TAARs (trace amine-associated receptors) are G-protein-coupled receptors that respond to low abundance, endogenous amines such as tyramine and tryptamine, and represent potential targets for neuropsychiatric diseases. However, some members of this ... Read more...

The synergistic interaction between morphine and maprotiline after intrathecal injection in rats.

29 Sep 2009 BACKGROUND: Antidepressant drugs act as potent inhibitors of norepinephrine and/or serotonin reuptake and are widely used with opioids for the treatment of chronic pain. The mechanism of this increased analgesic action is unclear. We compared the ... Read more...

[Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD]

30 Aug 2009 Attention Deficit Hyperactivity Disorder (ADHD) is not only a childhood disorder but symptoms persist into adolescence and adulthood in approximately one third of the patients. Especially inattention and poor concentration impair driving performance ... Read more...

Latest indexed articles for 'Adrenergic Uptake Inhibitors'

These are the very latest articles for this heading:

• Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands. 21 Oct 2009
• Rapid improvement in affective information processing after acute administration of reboxetine. 29 Sep 2009
• The synergistic interaction between morphine and maprotiline after intrathecal injection in rats. 29 Sep 2009
• [Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD] 30 Aug 2009
• Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. 30 Aug 2009
• Treatment of hyperkinetic movement disorders. 30 Aug 2009
• Flavin-containing monooxygenase 1-catalysed N,N-dimethylamphetamine N-oxidation. 30 Aug 2009
• Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. 30 Aug 2009
• Acute hippocampal sclerosis following ecstasy ingestion. 16 Aug 2009
• Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status. 30 Jul 2009
• Treatment effects of serotonergic and noradrenergic antidepressants on the intensity dependence of auditory ERP components in major depression. 14 Jul 2009
• Prenatal methamphetamine exposure affects the mesolimbic dopaminergic system and behavior in adult offspring. 6 Jul 2009
• Glucocorticoid status affects antidepressant regulation of locus coeruleus tyrosine hydroxylase and dorsal raphé tryptophan hydroxylase gene expression. Jul 2009
• Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. 30 Jun 2009
• Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template. 30 Jun 2009
• Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial. 29 Jun 2009
• Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion. 29 Jun 2009
• Second opinions improve ADHD prescribing in a medicaid-insured community population. 29 Jun 2009
• Treatment of chorea associated with Huntington's disease: focus on tetrabenazine. 29 Jun 2009
• Repeated exposure to MDMA provides neuroprotection against subsequent MDMA-induced serotonin depletion in brain. 21 Jun 2009

See a longer list of these articles.

Technical information about 'Adrenergic Uptake Inhibitors'

Definition: Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.

Registry Number: 0

Descriptor UI: D018759

Alternative terms: Adrenergic Uptake Inhibitors; Reuptake Inhibitors, Adrenergic; Inhibitors, Adrenergic Uptake; Uptake Inhibitors, Adrenergic; Inhibitors, Adrenergic Reuptake; Adrenergic Reuptake Inhibitors;

Related Mesh Headings: Amphetamines; Antidepressive Agents, Tricyclic; Dopamine Uptake Inhibitors;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.519.625.050.601; D27.505.519.625.600.050; D27.505.696.577.050.601; D27.505.696.577.600.050;

History Note: 95

Technical Notes: GEN or unspecified; prefer specifics; DF: ADREN UPTAKE INHIB